IGC Pharma

IGC

Market cap $38.2M

Overview Fund Activity

0.4201 USD

-0.0029

0.69%

At close Updated Sep 16, 11:12 AM EDT

1 day

-0.69%

5 days

3.09%

1 month

10.52%

3 months

40.93%

6 months

31.28%

Year to date

17.68%

1 year

19.52%

5 years

-65.28%

10 years

122.86%

About: IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Employees: 70

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

16% more funds holding

Funds holding: 25 [Q1] → 29 (+4) [Q2]

14% more capital invested

Capital invested by funds: $817K [Q1] → $930K (+$114K) [Q2]

0.22% more ownership

Funds ownership: 3.6% [Q1] → 3.82% (+0.22%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$4.5

971% upside

Avg. target

$4.5

971% upside

High target

$4.5

971% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Ascendiant Capital

Edward Woo

$4.5

Buy

Maintained

26 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about IGC published over the past 30 days

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

POTOMAC, MD / ACCESS Newswire / September 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced that its Artificial Intelligence (AI) team has been recognized with a special award for excellence in clean code development as part of the National Institute on Aging (NIA) PREPARE Challenge. The award highlights IGC Pharma's achievement in producing well-structured, transparent, and highly organized AI code that can be readily understood and reused by other researchers and developers.

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

POTOMAC, MD / ACCESS Newswire / September 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in Alzheimer's dementia, to a new international site at Island Health's Royal Jubilee Hospital in Victoria, British Columbia, Canada. "Bringing CALMA to Canada is a milestone in our mission to offer innovative solutions for individuals living with Alzheimer's disease," said Ram Mukunda, CEO of IGC Pharma.

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

POTOMAC, MD / ACCESS Newswire / August 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application US 17/613,909. The patent application, IGC510, is for a proprietary method for treating individuals suffering from stammering, stuttering, or Tourette's syndrome with THC and/or CBD.

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

POTOMAC, MD / ACCESS Newswire / August 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

POTOMAC, MD / ACCESS Newswire / August 25, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with Alzheimer's disease. The Company has added a clinical site at the Lynn Health Science Institute (LHSI) in Oklahoma City, Oklahoma.

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

POTOMAC, MARYLAND / ACCESS Newswire / August 19, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, reported its financial results for the quarter ended June 30, 2025. Highlights in the quarter include: Accelerated progress on the Company's Phase 2 CALMA trial in Alzheimer's disease Progress in the development of MINT-AD Extension of its undrawn $12M credit facility Ram Mukunda, CEO of IGC Pharma, commented, "We began fiscal 2026 with solid strategic momentum, advancing multiple programs that we believe position IGC for meaningful value creation this fiscal year.

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Zacks Investment Research

IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates

IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.

IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology POTOMAC, MARYLAND / ACCESS Newswire / August 12, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced promising preclinical results for IGC-M3, a novel small molecule designed to address multiple biological drivers of Alzheimer's disease. IGC-M3 demonstrated activity in laboratory models against beta-amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation, four key contributors to Alzheimer's pathology.

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

- New hope in Alzheimer's: IGC-M3 targets the disease on four fronts, showing promise in cellular models - POTOMAC, MD / ACCESS Newswire / August 5, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today announced encouraging preclinical data on its investigational molecule "IGC-M3". The invitro results demonstrates that IGC-M3 may offer disease-modifying potential by targeting multiple biological mechanisms central to Alzheimer's pathology, including amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation.

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

- Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings - POTOMAC, MARYLAND / ACCESS Newswire / July 23, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the presentation of three scientific posters at the 2025 Alzheimer's Association International Conference ("AAIC"), taking place July 27-31 in Toronto, Canada. The poster presentations highlight advancements in the Company's proprietary artificial intelligence ("AI") platforms designed to accelerate drug discovery and improve early detection of Alzheimer's disease, particularly in low-resource settings.

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

See News Rankings

Charts implemented using Lightweight Charts™